Ceribell (CBLL) Free Cash Flow Growth (1y) (2024 - 2026)
Ceribell (CBLL) Free Cash Flow Growth (1y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.91 Bn | 176.62 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 108.72 Bn | 99.50 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.85 Bn | 1.29 Bn | -109.40% |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 363.84% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | -31.71% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn | 133.09% |
| 10 | Ceribell | 673.23 Mn | 532.05 Mn | 23.12 Mn | -69.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.17% |
| Dec 31, 2025 | -17.05% |
| Sep 30, 2025 | -21.62% |
| Jun 30, 2025 | -8.91% |
| Mar 31, 2025 | -19.98% |
| Dec 31, 2024 | -26.64% |